- Home
- IGMS vs KUKE Comparison
IGMS vs KUKE Comparison
Compare IGMS & KUKE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IGMS
- KUKE
- Stock Information
- Founded
- IGMS 1993
- KUKE 2002
- Country
- IGMS United States
- KUKE China
- Employees
- IGMS N/A
- KUKE N/A
- Industry
- IGMS Biotechnology: Pharmaceutical Preparations
- KUKE Other Consumer Services
- Sector
- IGMS Health Care
- KUKE Real Estate
- Exchange
- IGMS Nasdaq
- KUKE Nasdaq
- Market Cap
- IGMS 82.1M
- KUKE 86.8M
- IPO Year
- IGMS 2019
- KUKE 2021
- Fundamental
- Price
- IGMS $1.36
- KUKE $2.90
- Analyst Decision
- IGMS Hold
- KUKE
- Analyst Count
- IGMS 8
- KUKE 0
- Target Price
- IGMS $6.00
- KUKE N/A
- AVG Volume (30 Days)
- IGMS 1.1M
- KUKE 8.8K
- Earning Date
- IGMS 08-13-2025
- KUKE 07-31-2025
- Dividend Yield
- IGMS N/A
- KUKE N/A
- EPS Growth
- IGMS N/A
- KUKE N/A
- EPS
- IGMS N/A
- KUKE N/A
- Revenue
- IGMS $2,681,000.00
- KUKE $9,442,397.00
- Revenue This Year
- IGMS $134.30
- KUKE N/A
- Revenue Next Year
- IGMS $22.37
- KUKE N/A
- P/E Ratio
- IGMS N/A
- KUKE N/A
- Revenue Growth
- IGMS 27.36
- KUKE N/A
- 52 Week Low
- IGMS $0.92
- KUKE $1.45
- 52 Week High
- IGMS $22.50
- KUKE $17.50
- Technical
- Relative Strength Index (RSI)
- IGMS 59.58
- KUKE 41.21
- Support Level
- IGMS $1.12
- KUKE $2.95
- Resistance Level
- IGMS $1.39
- KUKE $3.03
- Average True Range (ATR)
- IGMS 0.08
- KUKE 0.10
- MACD
- IGMS 0.01
- KUKE 0.03
- Stochastic Oscillator
- IGMS 83.87
- KUKE 47.60
About IGMS IGM Biosciences Inc.
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.
About KUKE Kuke Music Holding Limited
Kuke Music Holding Ltd provides classical music licensing, subscription, and education services in China. The company licenses its music content to online music entertainment platforms, such as Tencent Music Entertainment Group, digital music service providers, such as NetEase Cloud Music, as well as film and TV production companies, airlines, and smart hardware companies. Users can access the platform through the website, mobile app, and smart music devices.